CN102596983B - 交联型人工核苷和核苷酸 - Google Patents
交联型人工核苷和核苷酸 Download PDFInfo
- Publication number
- CN102596983B CN102596983B CN201080049279.2A CN201080049279A CN102596983B CN 102596983 B CN102596983 B CN 102596983B CN 201080049279 A CN201080049279 A CN 201080049279A CN 102596983 B CN102596983 B CN 102596983B
- Authority
- CN
- China
- Prior art keywords
- group
- compound
- amino
- nucleic acid
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1(C)O*(C(CO2)([C@@](C*)COCc3ccccc3)OCc3ccccc3)=C2O1 Chemical compound CC1(C)O*(C(CO2)([C@@](C*)COCc3ccccc3)OCc3ccccc3)=C2O1 0.000 description 8
- MJDQMQBSGZRXTC-WNACPCLMSA-N CC(C)(OC12)O[C@H]1O[C@](CCO)(COCc1ccccc1)C2OCc1ccccc1 Chemical compound CC(C)(OC12)O[C@H]1O[C@](CCO)(COCc1ccccc1)C2OCc1ccccc1 MJDQMQBSGZRXTC-WNACPCLMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009248979 | 2009-10-29 | ||
| JP2009-248979 | 2009-10-29 | ||
| JP2010-023209 | 2010-02-04 | ||
| JP2010023209 | 2010-02-04 | ||
| PCT/JP2010/068409 WO2011052436A1 (ja) | 2009-10-29 | 2010-10-19 | 架橋型人工ヌクレオシドおよびヌクレオチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102596983A CN102596983A (zh) | 2012-07-18 |
| CN102596983B true CN102596983B (zh) | 2016-06-15 |
Family
ID=43921860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080049279.2A Active CN102596983B (zh) | 2009-10-29 | 2010-10-19 | 交联型人工核苷和核苷酸 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8541562B2 (enExample) |
| EP (1) | EP2495248B1 (enExample) |
| JP (2) | JPWO2011052436A1 (enExample) |
| CN (1) | CN102596983B (enExample) |
| AU (1) | AU2010312751B2 (enExample) |
| CA (1) | CA2778171C (enExample) |
| WO (1) | WO2011052436A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9127280B2 (en) | 2010-08-31 | 2015-09-08 | Osaka University | Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient |
| EP2792746A4 (en) | 2011-12-12 | 2015-09-16 | Nat Cerebral & Cardiovascular Ct | OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE |
| ES2798301T3 (es) * | 2012-06-18 | 2020-12-10 | Daiichi Sankyo Co Ltd | Intermedio para producción de análogos de nucleósidos, y procedimiento para su producción |
| EP2899197B1 (en) * | 2012-09-21 | 2017-03-22 | Osaka University | Oligonucleotide and artificial nucleoside having guanidine bridge |
| WO2014109384A1 (ja) * | 2013-01-10 | 2014-07-17 | 塩野義製薬株式会社 | 架橋型核酸誘導体の製造方法 |
| WO2014112463A1 (ja) * | 2013-01-15 | 2014-07-24 | 国立大学法人大阪大学 | スルホンアミド構造を有するヌクレオシドおよびヌクレオチド |
| WO2014126229A1 (ja) | 2013-02-18 | 2014-08-21 | 塩野義製薬株式会社 | 含窒素複素環構造を有するヌクレオシド及びヌクレオチド |
| WO2015020194A1 (ja) * | 2013-08-09 | 2015-02-12 | 国立大学法人大阪大学 | Ａｃｓｌ１に対するアンチセンスオリゴヌクレオチド |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| WO2016006697A1 (ja) * | 2014-07-10 | 2016-01-14 | 賢二 中野 | アンチセンス抗悪性腫瘍剤 |
| CN107109411B (zh) | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| JP2018140938A (ja) * | 2015-07-24 | 2018-09-13 | 日産化学株式会社 | 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド |
| TW201718618A (zh) | 2015-09-18 | 2017-06-01 | 田邊三菱製藥股份有限公司 | 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物 |
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| CN116059236A (zh) | 2015-12-14 | 2023-05-05 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| US11234995B2 (en) * | 2016-01-07 | 2022-02-01 | Osaka University | α-synuclein expression inhibitor |
| EP3409779A4 (en) | 2016-01-26 | 2019-07-03 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| US11384112B2 (en) | 2016-02-17 | 2022-07-12 | Tokyo Institute Of Technology | Artificial nucleoside and artificial nucleotide, and artificial oligonucleotide |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| JP2020055750A (ja) * | 2017-01-30 | 2020-04-09 | 賢二 中野 | 癌浸潤または転移阻害核酸薬 |
| JP7188087B2 (ja) | 2017-02-06 | 2022-12-13 | 日産化学株式会社 | 一本鎖オリゴヌクレオチド |
| US11261440B2 (en) | 2017-02-21 | 2022-03-01 | Osaka University | Antisense oligonucleic acid |
| US11286275B2 (en) | 2017-02-21 | 2022-03-29 | Osaka University | Nucleic acid compound and oligonucleotide |
| EP3603648B1 (en) | 2017-03-29 | 2025-09-17 | Shionogi & Co., Ltd | Complex of nucleic acid medicine and multibranched lipid |
| WO2018180005A1 (ja) | 2017-03-31 | 2018-10-04 | 国立研究開発法人日本医療研究開発機構 | コンドロイチン硫酸生合成を阻害するアンチセンス核酸 |
| US11273222B2 (en) | 2017-05-26 | 2022-03-15 | National Cerebral And Cardiovascular Center | Antisense nucleic acid targeting PCSK9 |
| WO2019009298A1 (ja) * | 2017-07-05 | 2019-01-10 | 国立大学法人大阪大学 | α－シヌクレイン発現抑制剤 |
| US20200172903A1 (en) | 2017-07-05 | 2020-06-04 | Osaka University | ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION |
| US11555188B2 (en) | 2017-07-26 | 2023-01-17 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| KR20260009385A (ko) | 2017-08-25 | 2026-01-19 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| WO2019045075A1 (ja) | 2017-08-31 | 2019-03-07 | 田辺三菱製薬株式会社 | Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤 |
| EP3770256A4 (en) | 2018-03-20 | 2021-12-22 | Tokyo Institute of Technology | ANTISENSE OLIGONUCLEOTIDE WITH REDUCED TOXICITY |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| EP3831837A4 (en) * | 2018-07-31 | 2023-06-14 | Osaka University | OLIGONUCLEOTIDE THERAPEUTIC AGENT FOR SMALL CELL LUNG CANCER |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| JP7413362B2 (ja) | 2019-03-29 | 2024-01-15 | シスメックス株式会社 | 新規人工核酸、その製造方法及び用途 |
| KR20220024192A (ko) | 2019-05-31 | 2022-03-03 | 알리고스 테라퓨틱스 인코포레이티드 | 변형된 갭머 올리고뉴클레오타이드 및 사용 방법 |
| JP7692829B2 (ja) | 2019-07-30 | 2025-06-16 | 塩野義製薬株式会社 | Ｍｕｒｆ１を標的とする核酸医薬 |
| US20220282248A1 (en) | 2019-08-27 | 2022-09-08 | National University Corporation Tokai National Higher Education And Research System | Molecular targeted nucleic acid medicine for gastric cancer |
| WO2021127406A1 (en) * | 2019-12-19 | 2021-06-24 | The Regents Of The University Of California | Methods of producing target capture nucleic acids |
| WO2021132648A1 (ja) * | 2019-12-27 | 2021-07-01 | ルクサナバイオテク株式会社 | Ｒｅｃｑｌの発現を阻害するアンチセンスオリゴヌクレオチド及びその用途 |
| JP7773730B2 (ja) | 2020-03-02 | 2025-11-20 | 国立大学法人京都大学 | ｍｉＲ－３３ｂ阻害物質による動脈瘤の予防または治療 |
| CN115485381A (zh) | 2020-03-26 | 2022-12-16 | 国立研究开发法人国立循环器病研究中心 | 以apoc3为靶点的反义核酸 |
| JP2023522957A (ja) | 2020-04-21 | 2023-06-01 | フラッグシップ パイオニアリング， インコーポレイテッド | 二機能性分子およびその使用方法 |
| US12338437B2 (en) | 2020-05-11 | 2025-06-24 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| EP4219517A4 (en) | 2020-09-25 | 2024-09-25 | Riken Genesis Co., Ltd. | NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING THE SAME AND USE THEREOF |
| TWI910261B (zh) | 2020-11-06 | 2026-01-01 | 日商住友製藥股份有限公司 | Ｒｐｓ２５基因之表現及／或功能調節劑 |
| US20240148775A1 (en) | 2021-02-25 | 2024-05-09 | Osaka University | Oligonucleotide for inducing n-exon skipping during rest mrna precursor processing |
| EP4331606A4 (en) | 2021-04-30 | 2025-05-07 | Kyoto University | PREVENTION OR TREATMENT OF MYOPATHY USING A MIR-33B INHIBITOR |
| EP4335859A4 (en) | 2021-05-06 | 2025-07-30 | Luxna Biotech Co Ltd | METHOD FOR DESIGNING AN OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY |
| AU2022279820A1 (en) | 2021-05-28 | 2023-12-14 | Sumitomo Pharma Co., Ltd. | Antisense nucleic acid |
| WO2023026994A1 (ja) | 2021-08-21 | 2023-03-02 | 武田薬品工業株式会社 | ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート |
| WO2023127857A1 (ja) | 2021-12-27 | 2023-07-06 | 株式会社理研ジェネシス | 新規人工核酸、その製造方法及び用途 |
| US20250223596A1 (en) | 2022-03-17 | 2025-07-10 | Aichi Medical University | Antisense nucleic acid capable of inhibiting biosynthesis of chondroitin sulfate |
| JPWO2024101446A1 (enExample) | 2022-11-10 | 2024-05-16 | ||
| EP4674962A1 (en) | 2023-02-28 | 2026-01-07 | The University of Osaka | Oligonucleotide, and rest expression suppressing agent and pharmaceutical composition using same |
| JPWO2024257847A1 (enExample) | 2023-06-16 | 2024-12-19 | ||
| JPWO2025005265A1 (enExample) * | 2023-06-30 | 2025-01-02 | ||
| WO2025063261A1 (ja) | 2023-09-22 | 2025-03-27 | 塩野義製薬株式会社 | ウイルス由来タンパク質をコードするポリヌクレオチド |
| US20250368996A1 (en) | 2024-05-14 | 2025-12-04 | Aligos Therapeutics, Inc. | Modified antisense oligonucleotides for treating hepatitis b virus |
| WO2026149921A1 (en) * | 2025-01-09 | 2026-07-16 | Roche Molecular Systems, Inc. | Methods for producing rna molecules |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999060855A1 (en) * | 1998-05-26 | 1999-12-02 | Icn Pharmaceuticals, Inc. | Novel nucleosides having bicyclic sugar moiety |
| WO2005021570A1 (ja) * | 2003-08-28 | 2005-03-10 | Gene Design, Inc. | Ｎ−０結合性架橋構造型新規人工核酸 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| JP4383176B2 (ja) | 2002-02-13 | 2009-12-16 | 武 今西 | ヌクレオシド類縁体およびそのヌクレオチド類縁体を含むオリゴヌクレオチド誘導体 |
| US9127280B2 (en) * | 2010-08-31 | 2015-09-08 | Osaka University | Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient |
-
2010
- 2010-10-19 AU AU2010312751A patent/AU2010312751B2/en active Active
- 2010-10-19 CN CN201080049279.2A patent/CN102596983B/zh active Active
- 2010-10-19 CA CA2778171A patent/CA2778171C/en active Active
- 2010-10-19 WO PCT/JP2010/068409 patent/WO2011052436A1/ja not_active Ceased
- 2010-10-19 EP EP10826568.7A patent/EP2495248B1/en active Active
- 2010-10-19 US US13/502,611 patent/US8541562B2/en active Active
- 2010-10-19 JP JP2011538366A patent/JPWO2011052436A1/ja not_active Ceased
-
2013
- 2013-11-27 JP JP2013244692A patent/JP5669073B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999060855A1 (en) * | 1998-05-26 | 1999-12-02 | Icn Pharmaceuticals, Inc. | Novel nucleosides having bicyclic sugar moiety |
| WO2005021570A1 (ja) * | 2003-08-28 | 2005-03-10 | Gene Design, Inc. | Ｎ−０結合性架橋構造型新規人工核酸 |
Non-Patent Citations (3)
| Title |
|---|
| "Bioisosterism: a rational approach in drug design";George A. Patani，et al;《Chemical Reviews》;19960101;第96卷(第8期);第3156页表19，第3170页表48 * |
| "Synthesis and chemical properties of a novel 2′,4′-bridged nucleic acid analogue with a seven-membered cyclic carbamate structure";Masaru Nishida，et al;《Nucleic Acids Symposium Series》;20071120;第51卷(第1期);第157-158页 * |
| "Synthesis and properties of a novel 2’,4’-BNA bearing a urea bridged structure";Aiko Yahara, et al;《Nucleic Acids Symposium Series》;20090927;第53卷(第1期);第11-12页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010312751A1 (en) | 2012-06-14 |
| CA2778171C (en) | 2017-07-25 |
| EP2495248A4 (en) | 2013-10-16 |
| US8541562B2 (en) | 2013-09-24 |
| JPWO2011052436A1 (ja) | 2013-03-21 |
| CN102596983A (zh) | 2012-07-18 |
| JP5669073B2 (ja) | 2015-02-12 |
| AU2010312751B2 (en) | 2014-07-24 |
| US20120208991A1 (en) | 2012-08-16 |
| CA2778171A1 (en) | 2011-05-05 |
| JP2014043462A (ja) | 2014-03-13 |
| EP2495248A1 (en) | 2012-09-05 |
| WO2011052436A1 (ja) | 2011-05-05 |
| EP2495248B1 (en) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106103463B (zh) | 桥连型核苷和核苷酸 | |
| US8541569B2 (en) | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA | |
| JP5645840B2 (ja) | リン原子修飾核酸の合成方法 | |
| CN108137638B (zh) | 桥连型核酸GuNA、其制造方法及中间体化合物 | |
| US8354524B2 (en) | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids | |
| CN102596983A (zh) | 交联型人工核苷和核苷酸 | |
| WO2004106356A1 (en) | Functionalized nucleotide derivatives | |
| JP2002543214A (ja) | Ｌ−リボ−ｌｎａ類縁体 | |
| WO2002018388A1 (fr) | Analogues de nucleosides et derives d'oligonucleotides renfermant ces analogues | |
| JP2000095793A (ja) | ２’―ｏ―アルキル化グアノシン３’―ｏ―ホスホロアミダイト | |
| WO2018156056A1 (ru) | Модифицированные олигонуклеотиды, активирующие рнказу н | |
| CN106459135A (zh) | 双环核苷的合成 | |
| WO2007102581A1 (ja) | 2'水酸基修飾リボヌクレオシド誘導体 | |
| JP2001501581A (ja) | ヌクレオシド類似体 | |
| JP3119871B2 (ja) | オリゴデオキシリボヌクレオチド類 | |
| EP0611075A1 (en) | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | |
| Seela et al. | Phosphoramidites of base-modified 2′-deoxyinosine isosteres and solid-phase synthesis of d (GCI* CGC) oligomers containing an ambiguous base | |
| Ramzaeva et al. | Oligonucleotides Functionalized by Fluorescein and Rhodamine Dyes: Michael Addition of Methyl Acrylate to 2′‐Deoxypseudouridine | |
| Srivastava et al. | Achiral, acyclic nucleic acids: synthesis and biophysical studies of a possible prebiotic polymer | |
| CN103237780B (zh) | 核苷类似物或其盐、寡核苷酸类似物、基因表达抑制剂和用于检测基因的核酸探针 | |
| CN115151555A (zh) | 桥连型核苷和使用了该桥连型核苷的核苷酸 | |
| JP4882074B2 (ja) | オリゴヌクレオチド誘導体、遺伝子検出用プローブ及びｄｎａチップ | |
| EP1397377B1 (en) | Calix (4) arene-nucleoside and calix (4) arene-oligonucleotide hybrids | |
| JP7776154B2 (ja) | ホスホロチオエート及びボラノホスフェートを含むキメラ型核酸オリゴマー、及びその製造方法 | |
| Moriguchi et al. | Novel method of the synthesis and hybridization properties of an oligonucleotide containing non-ionic diisopropylsilyl internucleotide linkage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |